Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | THPO | P40225 | 2/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.76 |
| ▸ | GLA | P06280 | 1/20 | 0.76 |
| ▸ | EIF4E | P06730 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | TOP1 | P11387 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taribavirin SCHEMBL3868643 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL2619250 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL12758161 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL3307695 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL3307685 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL4967368 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL16330745 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL6981526 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL18735565 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL40670 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828409-B2 | Bridged-cyclo-ProTides as prodrugs of therapeutic nucleosides and nucleotides | ZHONG MINGHONG (US) | 2017-11-28 | — | — | US | disclosed |
| US-20120101157-A1 | 4,5-Diamino-3-Halo-2-Hydroxybenzoic Acid Derivatives and Preparations Thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-04-26 | — | — | US | disclosed |
| WO-2011076923-A9 | INHIBITOR FOR INOSINE MONOPHOSPHATE (IMP) DEHYDROGENASE AND/OR VIRAL RNA POLYMERASE FOR TREATMENT OF HEPATITIS E | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011076923-A1 | INHIBITOR FOR INOSINE MONOPHOSPHATE (IMP) DEHYDROGENASE AND/OR VIRAL RNA POLYMERASE FOR TREATMENT OF HEPATITIS E | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2011-06-30 | — | — | WO | disclosed |
| US-20100298256-A1 | ANTIVIRAL COMPOUNDS | EPIPHANY BIOSCIENCES, INC. | 2010-11-25 | — | — | US | disclosed |
| US-7816339-B2 | Treatments for Flaviviridae virus infection | SCHERING CORPORATION (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090209483-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | SCHERING CORPORATION | 2009-08-20 | — | — | US | disclosed |
| WO-2009085267-A1 | ANTIVIRAL COMPOUNDS | EPIPHANY BIOSCIENCES (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2008082601-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209483-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | HAVCR2, EIF2AK2, HNRNPC | PNP 131/4885LMNA 2114/4885SMN1; SMN2 3971/4885 |
| US-20120101157-A1 | 4,5-Diamino-3-Halo-2-Hydroxybenzoic Acid Derivatives and Preparations Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH3, HRH2 | PNP 1819/4885LMNA 3184/4885SMN1; SMN2 4664/4885 |
| US-20100298256-A1 | ANTIVIRAL COMPOUNDS | MTAP, PNP, TYMP | PNP 2/4885LMNA 2760/4885SMN1; SMN2 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.